ACAD
33.68
0.00
N/A%
AEMD
4.89
0.00
N/A%
APRI
0.343
0.00
N/A%
ARNA
1.77
0.00
N/A%
ATEC
8.98
0.00
N/A%
CNAT
2.06
-0.01
-0.48%
CRXM
0.2
0.00
N/A%
CYTX
2.02
0.00
N/A%
DXCM
89.74
0.00
N/A%
GNMK
11.69
0.00
N/A%
HALO
12.41
-0.1
-0.80%
ILMN
180.98
+0.63
+0.35%
INNV
0.26
0.00
N/A%
INO
9.54
-0.05
-0.52%
ISCO
1.85
0.00
N/A%
ISIS
57.56
0.00
0.00%
LGND
102.44
0.00
N/A%
LPTN
3.48
0.00
N/A%
MBVX
4.08
0.00
N/A%
MEIP
1.74
0.00
N/A%
MNOV
7.61
0.00
N/A%
MRTX
6.72
0.00
N/A%
MSTX
0.106
0.00
N/A%
NBIX
51.42
0.00
0.00%
NUVA
67.31
0.00
N/A%
ONCS
1.71
0.00
N/A%
ONVO
3.86
0.00
N/A%
OREX
3.29
0.00
N/A%
OTIC
17.07
0.00
N/A%
QDEL
21.91
0.00
N/A%
RCPT
231.96
0.00
0.00%
RGLS
3.45
0.00
N/A%
RMD
64.74
0.00
N/A%
SPHS
3.08
0.00
N/A%
SRNE
7.86
0.00
N/A%
TROV
4.49
0.00
N/A%
VICL
3.12
0.00
N/A%
VOLC
18
0.00
N/A%
ZGNX
11.21
0.00
N/A%
ACAD
33.68
0.00
N/A%
AEMD
4.89
0.00
N/A%
APRI
0.343
0.00
N/A%
ARNA
1.77
0.00
N/A%
ATEC
8.98
0.00
N/A%
CNAT
2.06
-0.01
-0.48%
CRXM
0.2
0.00
N/A%
CYTX
2.02
0.00
N/A%
DXCM
89.74
0.00
N/A%
GNMK
11.69
0.00
N/A%
HALO
12.41
-0.1
-0.80%
ILMN
180.98
+0.63
+0.35%
INNV
0.26
0.00
N/A%
INO
9.54
-0.05
-0.52%
ISCO
1.85
0.00
N/A%
ISIS
57.56
0.00
0.00%
LGND
102.44
0.00
N/A%
LPTN
3.48
0.00
N/A%
MBVX
4.08
0.00
N/A%
MEIP
1.74
0.00
N/A%
MNOV
7.61
0.00
N/A%
MRTX
6.72
0.00
N/A%
MSTX
0.106
0.00
N/A%
NBIX
51.42
0.00
0.00%
NUVA
67.31
0.00
N/A%
ONCS
1.71
0.00
N/A%
ONVO
3.86
0.00
N/A%
OREX
3.29
0.00
N/A%
OTIC
17.07
0.00
N/A%
QDEL
21.91
0.00
N/A%
RCPT
231.96
0.00
0.00%
RGLS
3.45
0.00
N/A%
RMD
64.74
0.00
N/A%
SPHS
3.08
0.00
N/A%
SRNE
7.86
0.00
N/A%
TROV
4.49
0.00
N/A%
VICL
3.12
0.00
N/A%
VOLC
18
0.00
N/A%
ZGNX
11.21
0.00
N/A%
Home » Archive by Category

Xconomy

CRISPR And Beyond: UCSD-Doudna Work Attracts Paul Allen’s Millions

March 23, 2016 – 2:33 pm

CRISPR-Cas9 is well known, by people who follow science and some who don’t, as the new DNA editing tool that one day might cure genetic diseases or lead to designer babies. Or both. Whether…

[[Click headline to continue reading.]]

Gilman Scores for Atlas Again as Bristol Buys Padlock for up to $600M

March 23, 2016 – 5:42 am

For the second time in just over four years, former Biogen research executive Michael Gilman has steered a startup towards a buyout. This time, it’s Padlock Therapeutics, a fledgling developer of…

[[Click headline to continue reading.]]

Dear Biopharma: Give Us Better Therapies for Pain

March 23, 2016 – 12:00 am

The CDC released on March 15th new guidelines that advise strict limits on the prescription of opioids for pain. These guidelines respond to a stunning increase in deaths and addiction related to the…

[[Click headline to continue reading.]]

Acutus Medical Raises $75M to Map Abnormal Currents of the Heart

March 22, 2016 – 3:00 am

Acutus Medical, a suburban San Diego medical device maker with new technology for diagnosing and treating irregular heartbeats, said today it has closed on $75 million in Series C funding. The…

[[Click headline to continue reading.]]

Big Data Meets Big Biology in San Diego, and Tickets Are Going Fast

March 22, 2016 – 12:00 am

Less than 15 tickets remain for next week’s Xconomy forum on Big Data Meets Big Biology. Join innovators in both data science and the life sciences on March 31st as they discuss how they are…

[[Click headline to continue reading.]]

West Coast Bio Roundup: Gilead Onco Woes, Adaptive Expansion & More

March 18, 2016 – 4:02 am

DiCE Molecules of Redwood City, CA, revealed itself this week with a new drug discovery scheme and a business model straight out of 2010. DiCE CEO Kevin Judice, a veteran of California biotechs that…

[[Click headline to continue reading.]]

Seattle’s Adaptive Bio to Base New Drug-Hunting Team in San Diego

March 17, 2016 – 12:17 pm

Diego Miralles, an immunologist and leader in HIV therapeutics, has joined Seattle’s Adaptive Biotechnologies to lead a new business initiative focused on developing new drugs for cancer, autoimmune,…

[[Click headline to continue reading.]]

Don’t Miss Your Chance to Save on Big Data Meets Big Biology

March 17, 2016 – 7:54 am

Our Big Data Meets Big Biology forum is only two weeks away, and today is your last chance to snag our Saver rate for the event. At this half-day event, we’ll be exploring a variety of topics at the…

[[Click headline to continue reading.]]

Don’t Miss Your Chance to Save on Big Data Meets Big Biology

March 17, 2016 – 7:54 am

Our Big Data Meets Big Biology forum is only two weeks away, and today is your last chance to snag our Saver rate for the event. At this half-day event, we’ll be exploring a variety of topics at the…

[[Click headline to continue reading.]]

Bird Rock Bio Nears Pivotal Trial of New Biologic Drug for RA

March 16, 2016 – 12:24 am

San Diego’s Bird Rock Bio says it is within a few months of submitting its plans in Brazil for a pivotal trial of gerilimzumab, a biologic drug for inflammatory diseases like rheumatoid arthritis…

[[Click headline to continue reading.]]